← Back to patent-cliff list
阿地溴铵/富马酸福莫特罗
Tier C — Watch / tradeAclidinium Bromide/Formoterol Fumarate Dihydrate
阿斯利康
Originator
2014
First approval
-
Expiry (public)
$0.1B ▲
Peak sales
化学药
Type
Targets：ADRB2、CHRM3
Brand：Duaklir Genuair、Brimica Genuair、Duaklir pressair
Indications (approved)：慢性阻塞性肺疾病
Regional status
US
批准上市
2019-03-29
EU
批准上市
2014-11-19
China
批准上市
2026-04-14
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Aclidinium Bromide/Formoterol Fumarate Dihydrate?
Approved indications include: 慢性阻塞性肺疾病.
When does the Aclidinium Bromide/Formoterol Fumarate Dihydrate patent expire?
No public expiry year is available for Aclidinium Bromide/Formoterol Fumarate Dihydrate yet; this page updates once verified.
How do I get a quote for Aclidinium Bromide/Formoterol Fumarate Dihydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24